Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Prostate cancer is a leading cause of cancer death in men, characterized by clinical heterogeneity.
• Tumor development progresses through stages: intraepithelial neoplasia, androgen-dependent, and castration-resistant adenocarcinoma.
• Molecular technologies have accelerated understanding of prostate cancer's genomic underpinnings.

Purpose of the Study:

• To elucidate the genomic landscape of prostate cancer.
• To identify distinct molecular subtypes and their associated genetic alterations.
• To understand the genomic events driving prostate cancer progression.

Main Methods:

• Analysis of prostate cancer genomes using advanced molecular technologies.
• Characterization of gene fusions, rearrangements, mutations, and deletions.
• Comparative genomic and transcriptomic profiling.

Main Results:

• Prostate cancer genomes exhibit a relatively low mutation rate with limited chromosomal copy number variations.
• Two primary molecular groups identified: ERG rearrangement-positive (~50% of cases) and ERG rearrangement-negative.
• ERG-negative cancers frequently feature SPOP mutations and/or CDH1 deletions, which are early developmental events.

Conclusions:

• Prostate cancer can be molecularly classified into distinct groups based on genetic alterations.
• ERG rearrangements define a major molecular subtype, while SPOP mutations and CDH1 alterations characterize another.
• Genomic and epigenomic changes accumulate during progression, leading to a heterogeneous transcriptomic profile and hyperactive androgen receptor signaling.